Todd Stallings-Schmitt

Todd Stallings-Schmitt joined ImmPACT in July 2022, and serves as Vice President, Clinical Development Operations. He brings with him more than 20 years of experience in clinical research and development operations, overseeing all phases of drug development.

Before joining ImmPACT, Todd was Vice President, Clinical Operations at PACT Pharma where he was responsible for the first-in-human trials of an autologous neoepitope-specific TCR T cell therapy for solid tumors. Prior to that he was Senior Director of Clinical Operations at Puma Biotechnology where he was responsible for multiple global clinical programs leading to an NDA and MAA filing resulting in approval of Nerlynx® (neratinib) for the treatment of HER2+ breast cancer in the extended adjuvant setting. Earlier in his career, Todd worked for BiPar Sciences (a Sanofi-Aventis company) and Genentech, overseeing clinical trials in orthopedics, cardiology, and oncology.

He received his Master Public Health from the University of Alabama at Birmingham, and Bachelor of Science degree in Biomedical Science from Auburn University.